Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 4, 2024

Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis

Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis

Mindpeak announces its collaboration with Sagis Dx to conduct a spearheading study, assessing the efficacy of the new Mindpeak Onychomycosis AI algorithm.

The Mindpeak Onychomycosis AI algorithm is designed to automate the process of detecting hyphae from multiple slides, by efficiently identifying target structures that may appear sparsely in whole-slide images. The algorithm aims to reduce the risk of missed diagnoses.

Read full article:https://lnkd.in/eHrpcezW

You may also be interested in

November 4, 2024
Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis

Mindpeak announces its collaboration with Sagis Dx to conduct a spearheading study, assessing the efficacy of the new Mindpeak Onychomycosis AI algorithm.

Read more ⟶
October 18, 2024
Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance

Read more ⟶
October 4, 2024
Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology

Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology Funding strengthens the product development roadmap for AI-powered histopathological assessments, supporting clinical labs and biopharma companies worldwide.

Read more ⟶

Find out more about our AI-based diagnostics

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mindpeak Breast IHC being displayed on a monitor

About Mindpeak

We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses.
‍
This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable. Explainable AI (xAI) results provide the required trust of pathologists into our tools.

Company information

Local court Hamburg HRB 151143
‍
Managing director:
Felix Faber
‍
V.A.T. identification number:
DE318495606

Founded in 2018

Contact us

Mindpeak GmbH
Zirkusweg 2
20359 Hamburg
Germany
Email: info@mindpeak.ai
Telephone: +49 40 35 67 67 97

Regulatory Note:
Unless otherwise stated all products are intended for Research Use Only, not for use in diagnostic procedures.

© 2024 Mindpeak GmbH

Supported by:

Horizon 2020 (European Commission)

Privacy policy

Contact